22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › IONIS PHARMACEUTICALS INC. › 2024-2025

IONIS PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and IONIS PHARMACEUTICALS INC.’s Form 8-K, filed June 10, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Ballot items
  • 378Asset managers, any item
  • 2,504Fund votes
  • June 5, 2025Meeting date

Results at a glance

Meeting of June 5, 2025: 7 items on IONIS PHARMACEUTICALS INC.’s Form 8-K, filed June 10, 2025: 4 elected · 3 approved.

Dissent

Significant dissent: 1 director (21.3% against).

Notable dissent: 1 other board item (21.8% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore IONIS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by IONIS PHARMACEUTICALS INC.

These tallies are IONIS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IONIS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 5, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Allene M. Diaz 134,533,6103,812,54964,043 --10,701,820 97%Elected—
Elect Director: Michael Hayden 133,250,5565,107,29552,351 --10,701,820 96%Elected—
Elect Director: Joseph Klein, III 127,135,69211,224,18250,328 --10,701,820 92%Elected—
Elect Director: Joseph Loscalzo 108,835,66229,465,062109,478 --10,701,820 79%Elected—
2. Advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as disclosed 132,567,6065,738,006104,590 --10,701,820 96%Approved—
3. Approval of an amendment of the Ionis Pharmaceuticals, Inc 108,160,71130,105,665143,826 --10,701,820 78%Approved—
4. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2025 fiscal year 144,587,5374,426,72897,757 --0 97%Approved—

Source: IONIS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 10, 2025 — read the filing on EDGAR.

How asset managers voted at the IONIS PHARMACEUTICALS INC. 2024-2025 meeting

378 asset managers disclosed a vote on at least one IONIS PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Allene M. Diaz

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 134,533,610AGAINST: 3,812,549
Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Election of Directors: Allene M. Diaz

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Allene M. Diaz”): 134,533,610 for, 3,812,549 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of directors to hold office until the 2028 Annual Meeting: The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 74,242,946 for, 2,494,224 against, 6,470 abstained, 59 not voted.

FOR
FOR: 74,242,946AGAINST: 2,494,224ABSTAIN: 6,470NOT VOTED: 59
Largest asset managers voting on “Election of Directors: Allene M. Diaz” at IONIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,957,6571 00For
Fidelity14,514,3230 00For
T. Rowe Price9,185,5572,349,933 00Mixed
Capital Group8,567,2780 00For
NEW ECONOMY FUND3,221,9270 00For
TWEEDY, BROWNE FUND INC.2,656,6690 00For
BlackRock2,650,3990 00For
Charles Schwab1,416,6250 00For
Waddell & Reed1,165,4230 00For
State Street1,123,2480 00For
Jackson National1,070,8130 00For
ARK ETF Trust1,004,3690 00For
MassMutual690,1441,336 00For
Invesco625,8270 00For
Aberdeen392,8360 00For
Empower378,1210 00For
Goldman Sachs342,1750 00For
TIAA273,7580 00For
Pacific Life235,4770 00For
Brighthouse131,54974,806 00Mixed
John Hancock140,71912,667 00Mixed
Artisan138,0970 00For
Hartford116,9320 00For
MASTER INVESTMENT PORTFOLIO113,5480 00For
Bridge Builder Trust109,5890 00For

Showing the 25 largest of 79 asset managers. All 79 are in the interactive database (link above).

Elect Director: Joseph Klein, III

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 127,135,692AGAINST: 11,224,182
Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Election of Directors: Joseph Klein, III

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Joseph Klein, III”): 127,135,692 for, 11,224,182 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of directors to hold office until the 2028 Annual Meeting: The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 72,632,027 for, 4,105,143 against, 6,470 abstained, 59 not voted.

FOR
FOR: 72,632,027AGAINST: 4,105,143ABSTAIN: 6,470NOT VOTED: 59
Largest asset managers voting on “Election of Directors: Joseph Klein, III” at IONIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,957,6562 00For
Fidelity14,514,3230 00For
T. Rowe Price9,185,5572,349,933 00Mixed
Capital Group8,567,2780 00For
NEW ECONOMY FUND3,221,9270 00For
TWEEDY, BROWNE FUND INC.2,656,6690 00For
BlackRock2,650,3990 00For
Charles Schwab1,416,6250 00For
Waddell & Reed1,165,4230 00For
State Street3,8111,119,437 00Against
Jackson National1,070,8130 00For
ARK ETF Trust1,004,3690 00For
MassMutual690,1441,336 00For
Invesco625,8270 00For
Aberdeen0392,836 00Against
Empower378,1210 00For
Goldman Sachs342,1750 00For
TIAA273,7580 00For
Pacific Life235,4770 00For
Brighthouse131,54974,806 00Mixed
John Hancock140,71912,667 00Mixed
Artisan138,0970 00For
Hartford116,9320 00For
MASTER INVESTMENT PORTFOLIO113,5480 00For
Bridge Builder Trust40,72968,860 00Mixed

Showing the 25 largest of 79 asset managers. All 79 are in the interactive database (link above).

Elect Director: Joseph Loscalzo

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST
FOR: 108,835,662AGAINST: 29,465,062
Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Election of Directors: Joseph Loscalzo

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Joseph Loscalzo”): 108,835,662 for, 29,465,062 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of directors to hold office until the 2028 Annual Meeting: The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 60,359,776 for, 16,377,393 against, 6,470 abstained, 59 not voted.

FORAGAINST
FOR: 60,359,776AGAINST: 16,377,393ABSTAIN: 6,470NOT VOTED: 59
Largest asset managers voting on “Election of Directors: Joseph Loscalzo” at IONIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,955,1332,525 00For
Fidelity14,514,3230 00For
T. Rowe Price011,535,490 00Against
Capital Group8,567,2780 00For
NEW ECONOMY FUND3,221,9270 00For
TWEEDY, BROWNE FUND INC.2,656,6690 00For
BlackRock2,650,3990 00For
Charles Schwab1,416,6250 00For
Waddell & Reed1,165,4230 00For
State Street3,8111,119,437 00Against
Jackson National01,070,813 00Against
ARK ETF Trust1,004,3690 00For
MassMutual0691,480 00Against
Invesco0625,827 00Against
Aberdeen392,8360 00For
Empower0378,121 00Against
Goldman Sachs0342,175 00Against
TIAA273,7580 00For
Pacific Life235,4770 00For
Brighthouse0206,355 00Against
John Hancock129,89523,491 00Mixed
Artisan138,0970 00For
Hartford116,9320 00For
MASTER INVESTMENT PORTFOLIO113,5480 00For
Bridge Builder Trust40,72968,860 00Mixed

Showing the 25 largest of 79 asset managers. All 79 are in the interactive database (link above).

Elect Director: Michael Hayden

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 133,250,556AGAINST: 5,107,295
Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Election of Directors: Michael Hayden

IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael Hayden”): 133,250,556 for, 5,107,295 against, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of directors to hold office until the 2028 Annual Meeting: The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 74,242,942 for, 2,494,228 against, 6,470 abstained, 59 not voted.

FOR
FOR: 74,242,942AGAINST: 2,494,228ABSTAIN: 6,470NOT VOTED: 59
Largest asset managers voting on “Election of Directors: Michael Hayden” at IONIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,957,6571 00For
Fidelity14,514,3230 00For
T. Rowe Price9,185,5572,349,933 00Mixed
Capital Group8,567,2780 00For
NEW ECONOMY FUND3,221,9270 00For
TWEEDY, BROWNE FUND INC.2,656,6690 00For
BlackRock2,650,3990 00For
Charles Schwab1,416,6250 00For
Waddell & Reed1,165,4230 00For
State Street1,123,2480 00For
Jackson National1,070,8130 00For
ARK ETF Trust1,004,3690 00For
MassMutual690,1441,336 00For
Invesco625,8270 00For
Aberdeen392,8360 00For
Empower378,1210 00For
Goldman Sachs342,1750 00For
TIAA273,7580 00For
Pacific Life235,4770 00For
Brighthouse131,54974,806 00Mixed
John Hancock140,71912,667 00Mixed
Artisan138,0970 00For
Hartford116,9320 00For
MASTER INVESTMENT PORTFOLIO113,5480 00For
Bridge Builder Trust109,5890 00For

Showing the 25 largest of 79 asset managers. All 79 are in the interactive database (link above).

Approval of an amendment of the Ionis Pharmaceuticals, Inc

Official resultCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

78% Approved · of votes cast

FOR 78%AGAINST
FOR: 108,160,711AGAINST: 30,105,665
Details: description as filed, official tally, votes by 81 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT OF THE IONIS PHARMACEUTICALS, INC. 2011 EQUITY INCENTIVE PLAN TO INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER SUCH PLAN BY 4,000,000 SHARES TO AN AGGREGATE OF 42,500,000 SHARES.

IONIS PHARMACEUTICALS INC.’s own tally for this item (“3. Approval of an amendment of the Ionis Pharmaceuticals, Inc”): 108,160,711 for, 30,105,665 against — passed, per its Form 8-K filed June 10, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 81 asset managers below reported 61,670,833 for, 15,022,346 against, 6,470 abstained, 59 not voted.

FORAGAINST
FOR: 61,670,833AGAINST: 15,022,346ABSTAIN: 6,470NOT VOTED: 59
Largest asset managers voting on “TO APPROVE AN AMENDMENT OF THE IONIS PHARMACEUTICALS, INC. 2011 EQUITY INCENTIVE PLAN TO INCREASE THE AGGREGAT” at IONIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,957,6526 00For
Fidelity2,217,68412,296,639 00Mixed
T. Rowe Price11,535,4900 00For
Capital Group8,567,2780 00For
NEW ECONOMY FUND3,221,9270 00For
TWEEDY, BROWNE FUND INC.02,656,669 00Against
BlackRock2,650,3990 00For
Charles Schwab1,416,6250 00For
Waddell & Reed1,165,4230 00For
State Street1,123,23711 00For
Jackson National1,070,8130 00For
ARK ETF Trust1,004,3690 00For
MassMutual691,4800 00For
Invesco625,8270 00For
Aberdeen392,8360 00For
Empower378,1210 00For
Goldman Sachs342,1750 00For
TIAA273,7580 00For
Pacific Life235,4770 00For
Brighthouse206,3550 00For
John Hancock153,3860 00For
Artisan138,0970 00For
Hartford116,9320 00For
MASTER INVESTMENT PORTFOLIO113,5480 00For
Bridge Builder Trust109,5890 00For

Showing the 25 largest of 81 asset managers. All 81 are in the interactive database (link above).

Advisory vote on the compensation paid to the Company's executive officers, including the following resolution…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 132,567,606AGAINST: 5,738,006

Prior year: 96.6% for (June 6, 2024 meeting) ▼ 0.7 pts

Details: description as filed, official tally, votes by 378 asset managers

Description as filed by funds: To make an advisory vote on executive compensation.

IONIS PHARMACEUTICALS INC.’s own tally for this item (“2. An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of th”): 132,567,606 for, 5,738,006 against — passed, per its Form 8-K filed June 10, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 78 asset managers voting on “To make an advisory vote on executive compensation.” at IONIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,954,7252,933 00For
Fidelity14,514,3230 00For
T. Rowe Price11,535,4900 00For
Capital Group8,567,2780 00For
NEW ECONOMY FUND3,221,9270 00For
TWEEDY, BROWNE FUND INC.2,656,6690 00For
BlackRock2,650,3990 00For
Charles Schwab1,416,6250 00For
Waddell & Reed1,165,4230 00For
State Street1,121,9741,274 00For
Jackson National1,070,8130 00For
ARK ETF Trust1,004,3690 00For
MassMutual691,4800 00For
Invesco625,8270 00For
Aberdeen392,8360 00For
Empower378,1210 00For
Goldman Sachs342,1750 00For
TIAA0273,758 00Against
Pacific Life235,4770 00For
Brighthouse206,3550 00For
John Hancock153,3860 00For
Artisan138,0970 00For
Hartford116,9320 00For
MASTER INVESTMENT PORTFOLIO113,5480 00For
Bridge Builder Trust109,5890 00For

Fund voting reports, all 78 managers: 76,257,600 for, 428,399 against, 6,470 abstained, 59 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 322 asset managers voting on “To make an advisory vote on executive compensation.” at IONIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity23,178,6930 00For
T. Rowe Price18,847,9770 00For
Capital Group12,373,9620 00For
Wellington8,107,1850 00For
Deep Track Capital, LP4,933,7840 00For
BlackRock3,878,8550 00For
State Street3,294,1691,274 00For
Tweedy, Browne Co LLC2,865,6130 00For
ORBIMED ADVISORS LLC2,540,1360 00For
GEODE CAPITAL MANAGEMENT, LLC1,969,2210 00For
BVF INC/IL1,913,3850 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST1,597,1890 00For
Charles Schwab1,447,5300 00For
BNP Paribas Asset Management Holding S.A.01,203,742 00Against
Candriam S.C.A.0820,451 00Against
Camber Capital Management LP725,0000 00For
Invesco722,2270 00For
Northern Trust662,0220 00For
PICTET ASSET MANAGEMENT SA604,2460 00For
AXA INVESTMENT MANAGERS UK Ltd0566,486 00Against
GROUPAMA ASSET MANAGMENT0529,418 00Against
GW&K Investment Management, LLC462,8490 00For
Logos Global Management LP450,0000 00For
Aberdeen446,1970 00For
Vanguard432,5410 00For

Institutional-manager reports, all 322 managers: 98,523,303 for, 5,043,535 against, 1,443 abstained, 2,992 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2025 fiscal year

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 144,587,537AGAINST: 4,426,728

Prior year: 97.4% for (June 6, 2024 meeting) ▼ 0.4 pts

Details: description as filed, official tally, votes by 81 asset managers

Description as filed by funds: TO RATIFY THE AUDIT COMMITTEE'S SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT AUDITORS FOR THE 2025 FISCAL YEAR.

IONIS PHARMACEUTICALS INC.’s own tally for this item (“4. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2025 fiscal year”): 144,587,537 for, 4,426,728 against — passed, per its Form 8-K filed June 10, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 81 asset managers below reported 76,320,257 for, 416,986 against, 6,470 abstained, 59 not voted.

FOR
FOR: 76,320,257AGAINST: 416,986ABSTAIN: 6,470NOT VOTED: 59
Largest asset managers voting on “TO RATIFY THE AUDIT COMMITTEE'S SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT AUDITORS FOR THE 2025 FISCAL YEA” at IONIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,955,1392,519 00For
Fidelity14,514,3230 00For
T. Rowe Price11,535,4900 00For
Capital Group8,567,2780 00For
NEW ECONOMY FUND3,221,9270 00For
TWEEDY, BROWNE FUND INC.2,656,6690 00For
BlackRock2,650,3990 00For
Charles Schwab1,416,6250 00For
Waddell & Reed1,165,4230 00For
State Street1,123,20543 00For
Jackson National1,070,8130 00For
ARK ETF Trust1,004,3690 00For
MassMutual691,4800 00For
Invesco625,8270 00For
Aberdeen0392,836 00Against
Empower378,1210 00For
Goldman Sachs342,1750 00For
TIAA273,7580 00For
Pacific Life235,4770 00For
Brighthouse206,3550 00For
John Hancock153,3860 00For
Artisan138,0970 00For
Hartford116,9320 00For
MASTER INVESTMENT PORTFOLIO113,5480 00For
Bridge Builder Trust109,5890 00For

Showing the 25 largest of 81 asset managers. All 81 are in the interactive database (link above).

Largest IONIS PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 159,041,259 shares outstanding at the time of that meeting.

Fund voting reports: top IONIS PHARMACEUTICALS INC. shareholders by shares voted on “To make an advisory vote on executive compensation.”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 14.44%
2Fidelity 9.13%
3T. Rowe Price 7.25%
4Capital Group 5.39%
5NEW ECONOMY FUND 2.03%
6TWEEDY, BROWNE FUND INC. 1.67%
7BlackRock 1.67%
8Charles Schwab 0.89%
9Waddell & Reed 0.73%
10State Street 0.71%
Institutional-manager reports: top IONIS PHARMACEUTICALS INC. shareholders by shares voted on “To make an advisory vote on executive compensation.”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 14.57%
2T. Rowe Price 11.85%
3Capital Group 7.78%
4Wellington 5.10%
5Deep Track Capital, LP 3.10%
6BlackRock 2.44%
7State Street 2.07%
8Tweedy, Browne Co LLC 1.80%
9ORBIMED ADVISORS LLC 1.60%
10GEODE CAPITAL MANAGEMENT, LLC 1.24%

Reported IONIS PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

IONIS PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)23,613,585 14.85%Form 13F, quarter ended March 31, 2025
FMR LLC21,520,872 13.53%Proxy statement (DEF 14A), proxy filed April 25, 2025
Capital World Investors21,186,369 13.32%Schedule 13G, filed May 14, 2026
Vanguard Group16,383,934 10.30%Form 13F, quarter ended March 31, 2025
BlackRock11,264,442 7.08%Form 13F, quarter ended March 31, 2025
BlackRock Institutional Trust Company, N.A9,057,282 5.69%Proxy statement (DEF 14A), proxy filed April 25, 2025
Wellington Management8,416,421 5.29%Form 13F, quarter ended March 31, 2025
State Street4,845,133 3.05%Form 13F, quarter ended March 31, 2025
Citadel Advisors3,615,962 2.27%Form 13F, quarter ended March 31, 2025
T. Rowe Price3,265,034 2.05%Form 13F, quarter ended March 31, 2025

Percentages above are of 159,041,259 shares outstanding, as reported by IONIS PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At IONIS PHARMACEUTICALS INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 378 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 2,504 separate fund positions. On the most widely held item on that ballot — To make an advisory vote on executive compensation. — IONIS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: IONIS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IONIS PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

IONIS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “IONIS PHARMACEUTICALS (IONS) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ionis-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.